<DOC>
	<DOCNO>NCT02817750</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics new formulation zolpidem hemitartarate orodispersible tablet 3.5 mg male female healthy volunteer .</brief_summary>
	<brief_title>Pharmacokinetics Study Zolpidem Hemitartarate Orodispersible Tablet 3.5 mg Formulation</brief_title>
	<detailed_description>This phase I study zolpidem hemitartarate orodispersible tablet 3.5 mg fast postprandial administration . Sample size 28 volunteer , male female , age 18 50 year old . This open-label , randomize , crossover study . Each volunteer randomize one follow sequencies : - Sequency 1 : zolpidem hemitartarate orodispersible tablet 3.5 mg fasting ( period 1 ) zolpidem hemitartarate orodispersible tablet 3.5 mg postprandial ( period 2 ) - Sequency 2 : zolpidem hemitartarate orodispersible tablet 3.5 mg postprandial ( period 1 ) zolpidem hemitartarate orodispersible tablet 3.5 mg fasting ( period 2 ) Formulation administer single dose , orally period . The volunteer admit two different period 36 hour , investigational product administer blood sample collect pre-determined period time 24 hour pharmacokinetics evaluation . Primary objective evaluate pharmacokinetics new formulation zolpidem hemitartarate orodispersible tablet 3.5 mg healthy volunteer . As secondary objective , evaluate pharmacokinetics difference gender .</detailed_description>
	<mesh_term>Zolpidem</mesh_term>
	<criteria>Male female volunteer , age 18 50 year old ( woman pregnant breastfeed period commit use effective contraceptive method study ) Body mass index ( BMI ) great equal 18.5 less equal 29.9 kg/m2 Good health condition without significant disease , accord best medical judgment , accord medical history , blood pressure heart rate measurement , pulse , temperature , physical examination , electrocardiogram ( ECG ) complementary laboratory test Ability understand nature objective trial , include risk adverse event , willingness cooperate researcher proceed accord study requirement , shall confirm informed consent form signature . Know hypersensitivity investigational product ( Zolpidem ) chemically related compound History presence hepatic gastrointestinal disease , condition interferes drug absorption , distribution , excretion metabolism Maintenance therapy drug , except oral contraceptive History hepatic , kidney , lung , gastrointestinal , epileptic , hematologic , psychiatric , cardiologic allergic disease etiology , require pharmacological treatment consider clinically relevant investigator Electrocardiographic finding investigator discretion recommend study participation Deviations screen laboratory result consider clinically relevant investigator Smoking Intake five cup coffee tea per day History abusive use drug alcohol Use regular medication two week prior study enrollment use medication one week prior study enrollment Hospitalization reason 8 week prior start first period trial treatment Treatment within 3 month prior start trial treatment , drug know wellestablished toxic potential major organ Participation pharmacokinetics trial 300 mL blood draw administration experimental drug within 12 month prior trial treatment start Donation loss 450 mL blood within 3 month prior trial enrollment donation 1500 mL blood within 12 month prior trial treatment start Positive result BHCG urine test , perform female subject Positive result detection abusive drug urine exam Result high 0.1 mg/L etilometer exam Any condition , accord investigator 's best judgment , prevents subject participate trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>volunteer</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>